TNF-α-IN-29

TNF-α-IN-29 (XS-18) binds strongly to human TNF-α protein with an FP-IC₅₀ of 123.0 nM and a K_d of 45.9 nM, and inhibits the protein-protein interaction between TNF-α and TNFR1 with an IC₅₀ of 36.4 nM.
TNF-α-IN-29 (up to 60 min) has enhanced in vitro metabolic stability in human liver microsomes with a half-life of 63.6 min^[1].
TNF-α-IN-29 (1.37-1000 nM; 1.5 h preincubated with TNF-α, 24 h incubated with cells) neutralizes TNF-α-induced apoptosis in L929 cells^[1].
TNF-α-IN-29 (20 min preincubated with TNF-α, 18 h incubated with cells) inhibits TNF-α-induced NF-κB activation in NF-κB-TA-Luc HEK293 cells with an IC₅₀ of 126.9 nM and exhibits minimal cytotoxicity at 20 μM^[1].
TNF-α-IN-29 (5-10 μM; 72 h incubated with cells, 15 min stimulated with TNF-α) blocks TNF-α-mediated NF-κB pathway activation in MH7A cells by reducing IκBα phosphorylation and suppresses IL-6 mRNA expression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.